An anti-equol antibody composition, containing an anti-equol antibody or antibody fragment thereof containing, as an immunoglobulin heavy chain variable region, hypervariable regions CDR1, CDR2, and CDR3 respectively including amino acid sequences represented by SEQ ID NO: 1-3, and as an immunoglobulin light chain variable region, hypervariable regions CDR1, CDR2, and CDR3 respectively including amino acid sequences represented by SEQ ID NO: 4-6; and an anti-equol antibody or antibody fragment thereof containing, as an immunoglobulin heavy chain variable region, hypervariable regions CDR1, CDR2, and CDR3 respectively including amino acid sequences represented by SEQ ID NO: 1-3, and as an immunoglobulin light chain variable region, hypervariable regions CDR1, CDR2, and CDR3 respectively including amino acid sequences represented by SEQ ID NO: 7-9.

A method of making an antibody in plants that binds to ricin is described. The method comprises (a) introducing a nucleic acid molecule encoding a heavy chain variable region of the antibody and a nucleic acid molecule encoding a light chain variable region of the antibody into a plant or plant cell; and (b) growing the plant or plant cell to obtain a plant that expresses the antibody or antibody fragment. The disclosure also relates to anti-ricin antibodies and antibodies fragments as well as methods of using same in therapy and prophylaxis.

A method of making an antibody in plants that binds to ricin is described. The method comprises (a) introducing a nucleic acid molecule encoding a heavy chain variable region of the antibody and a nucleic acid molecule encoding a light chain variable region of the antibody into a plant or plant cell; and (b) growing the plant or plant cell to obtain a plant that expresses the antibody or antibody fragment. The disclosure also relates to anti-ricin antibodies and antibodies fragments as well as methods of using same in therapy and prophylaxis.

Methods, compositions and kits are provided for treating a subject exposed to or at risk for exposure to a disease agent using a pharmaceutical composition including at least one recombinant binding protein or a source of expression of the binding protein, wherein the binding protein neutralizes a disease agent that is a toxin, for example a Clostridium difficile toxin, a Shiga toxin, a ricin toxin, or an anthrax toxin.

Methods, compositions and kits are provided for treating a subject exposed to or at risk for exposure to a disease agent using a pharmaceutical composition including at least one recombinant binding protein or a source of expression of the binding protein, wherein the binding protein neutralizes a disease agent that is a toxin, for example a Clostridium difficile toxin, a Shiga toxin, a ricin toxin, or an anthrax toxin.

Methods and system for protein characterization using online chromatography and electrospray ionization mass spectrometry are provided.

Methods and system for protein characterization using online chromatography and electrospray ionization mass spectrometry are provided.

The invention provides anti-Ara h 2 antibodies (e.g., an anti-Ara h 2 neutralizing antibody) and methods of using the same, e.g., for treating and/or preventing peanut allergy or sensitivity. Also provided herein are anti-Ara h 2 antibodies and methods of using the same, e.g., for diagnostics and methods of monitoring peanut oral immunotherapy. Also provided are combinations of anti-Ara h 2 antibodies for use in determining a treatment response of an individual with a peanut allergy to peanut exposure. Also provided are methods for assessing a treatment response of an individual with a peanut allergy to peanut exposure.

The invention provides anti-Ara h 2 antibodies (e.g., an anti-Ara h 2 neutralizing antibody) and methods of using the same, e.g., for treating and/or preventing peanut allergy or sensitivity. Also provided herein are anti-Ara h 2 antibodies and methods of using the same, e.g., for diagnostics and methods of monitoring peanut oral immunotherapy. Also provided are combinations of anti-Ara h 2 antibodies for use in determining a treatment response of an individual with a peanut allergy to peanut exposure. Also provided are methods for assessing a treatment response of an individual with a peanut allergy to peanut exposure.

The invention relates to a new gene that produces a protein which is capable of inferring oomycete resistance, more preferably resistance to Phytophthora infestans when expressed in a plant, wherein said nucleotide sequence encodes a protein that is encoded by the protein produced by the nucleotide sequence of FIG. 10 or the protein depicted in FIG. 11 or a nucleotide sequence that codes for a protein that has an identity of at least 95% with said protein produced by the nucleotide sequence of FIG. 10 or the protein depicted in FIG. 11. The invention also relates to a method for providing at least partial resistance or increasing resistance in a plant against an oomycete infection comprising providing a plant or a part thereof with a nucleotide sequence as indicated above or a functional fragment thereof, preferably wherein said plant is a plant from the Solanaceae family, more preferably Solanum tuberosum.